{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:05:35Z","timestamp":1790665535661,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["Bristol-Myers Squibb"],"award-info":[{"award-number":["Bristol-Myers Squibb"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"DOI":"10.1007\/s00259-026-08188-4","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:31:13Z","timestamp":1790663473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PD-L1 PET\/CT imaging with 18F-BMS-986,229 and 18F-BMS-986,192 in patients with advanced-stage non-small cell lung cancer"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8233-1307","authenticated-orcid":false,"given":"Jasper","family":"Smit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Borm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke R.","family":"Gerards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne E.","family":"Wiegers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Holden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik J.","family":"Grootendorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Windhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeel","family":"Nabulsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Gettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert F.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianus J.","family":"de Langen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"8188_CR1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:358\u201376. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.013.","journal-title":"Ann Oncol"},{"key":"8188_CR2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502931","author":"PM Forde","year":"2025","unstructured":"Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, et al. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2502931.","journal-title":"N Engl J Med"},{"key":"8188_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/s1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:198\u2013211. https:\/\/doi.org\/10.1016\/s1470-2045(20)30641-0.","journal-title":"Lancet Oncol"},{"key":"8188_CR4","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378:2078\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1801005.","journal-title":"N Engl J Med"},{"key":"8188_CR5","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375:1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"N Engl J Med"},{"key":"8188_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","volume":"12","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017;12:208\u201322. https:\/\/doi.org\/10.1016\/j.jtho.2016.11.2228.","journal-title":"J Thorac Oncol"},{"key":"8188_CR7","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","volume":"13","author":"MS Tsao","year":"2018","unstructured":"Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, et al. PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. J Thorac Oncol. 2018;13:1302\u201311. https:\/\/doi.org\/10.1016\/j.jtho.2018.05.013.","journal-title":"J Thorac Oncol"},{"key":"8188_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002230","author":"MK Moutafi","year":"2021","unstructured":"Moutafi MK, Tao W, Huang R, Haberberger J, Alexander B, Ramkissoon S, et al. Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-002230.","journal-title":"J Immunother Cancer"},{"key":"8188_CR9","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","volume":"9","author":"AN Niemeijer","year":"2018","unstructured":"Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen G, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun. 2018;9:4664. https:\/\/doi.org\/10.1038\/s41467-018-07131-y.","journal-title":"Nat Commun"},{"key":"8188_CR10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2967\/jnumed.121.261926","volume":"63","author":"AN Niemeijer","year":"2022","unstructured":"Niemeijer AN, Oprea-Lager DE, Huisman MC, Hoekstra OS, Boellaard R, de Wit-van BJ, et al. Study of (89)Zr-Pembrolizumab PET\/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer. J Nucl Med. 2022;63:362\u20137. https:\/\/doi.org\/10.2967\/jnumed.121.261926.","journal-title":"J Nucl Med"},{"key":"8188_CR11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2967\/jnumed.121.262473","volume":"63","author":"J Smit","year":"2022","unstructured":"Smit J, Borm FJ, Niemeijer AN, Huisman MC, Hoekstra OS, Boellaard R, et al. PD-L1 PET\/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer. J Nucl Med. 2022;63:686\u201393. https:\/\/doi.org\/10.2967\/jnumed.121.262473.","journal-title":"J Nucl Med"},{"key":"8188_CR12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2967\/jnumed.121.262368","volume":"63","author":"PH Nienhuis","year":"2022","unstructured":"Nienhuis PH, Antunes IF, Glaudemans A, Jalving M, Leung D, Noordzij W, et al. (18)F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study. J Nucl Med. 2022;63:899\u2013905. https:\/\/doi.org\/10.2967\/jnumed.121.262368.","journal-title":"J Nucl Med"},{"key":"8188_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2967\/jnumed.117.199596","volume":"59","author":"DJ Donnelly","year":"2018","unstructured":"Donnelly DJ, Smith RA, Morin P, Lipov\u0161ek D, Gokemeijer J, Cohen D, et al. Synthesis and Biologic Evaluation of a Novel (18)F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression. J Nucl Med. 2018;59:529\u201335. https:\/\/doi.org\/10.2967\/jnumed.117.199596.","journal-title":"J Nucl Med"},{"key":"8188_CR14","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1007\/s00259-023-06527-3","volume":"51","author":"DJ Donnelly","year":"2024","unstructured":"Donnelly DJ, Kim J, Tran T, Scola PM, Tenney D, Pena A, et al. The discovery and evaluation of [(18)F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement. Eur J Nucl Med Mol Imaging. 2024;51:978\u201390. https:\/\/doi.org\/10.1007\/s00259-023-06527-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8188_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.2967\/jnumed.123.267186","volume":"65","author":"SL Cytryn","year":"2024","unstructured":"Cytryn SL, Pandit-Taskar N, Lumish MA, Maron SB, Gu P, Ku GY, et al. (18)F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer. J Nucl Med. 2024;65:722\u20137. https:\/\/doi.org\/10.2967\/jnumed.123.267186.","journal-title":"J Nucl Med"},{"key":"8188_CR16","unstructured":"Gettinger SBT, Yang X et al. CheckMate 592: a phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC. In: doi:10.1093\/annonc\/mdy292.124 AOsm-m, editor. CheckMate 592: a phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC."},{"key":"8188_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"8188_CR18","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2967\/jnumed.118.211607","volume":"59","author":"R Boellaard","year":"2018","unstructured":"Boellaard R. Quantitative oncology molecular analysis suite: ACCURATE. J Nucl Med. 2018;59:1753.","journal-title":"J Nucl Med"},{"key":"8188_CR19","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1007\/s00259-011-1899-5","volume":"38","author":"P Cheebsumon","year":"2011","unstructured":"Cheebsumon P, Yaqub M, van Velden FH, Hoekstra OS, Lammertsma AA, Boellaard R. Impact of [\u00b9\u2078F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology. Eur J Nucl Med Mol Imaging. 2011;38:2136\u201344. https:\/\/doi.org\/10.1007\/s00259-011-1899-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8188_CR20","doi-asserted-by":"publisher","first-page":"e268","DOI":"10.1111\/ajco.13605","volume":"18","author":"Z Wei","year":"2022","unstructured":"Wei Z, Fan L, Yang X, Li J, Zhan X, Ye X. PD-L1 heterogeneity in patients with non-small cell lung cancer. Asia Pac J Clin Oncol. 2022;18:e268\u201374. https:\/\/doi.org\/10.1111\/ajco.13605.","journal-title":"Asia Pac J Clin Oncol"},{"key":"8188_CR21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","volume":"143","author":"K Kulangara","year":"2019","unstructured":"Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D, et al. Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer. Arch Pathol Lab Med. 2019;143:330\u20137. https:\/\/doi.org\/10.5858\/arpa.2018-0043-OA.","journal-title":"Arch Pathol Lab Med"},{"key":"8188_CR22","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381:2020\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1910231.","journal-title":"N Engl J Med"},{"key":"8188_CR23","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","volume":"27","author":"T Cascone","year":"2021","unstructured":"Cascone T, William WN Jr., Weissferdt A, Leung CH, Lin HY, Pataer A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27:504\u201314. https:\/\/doi.org\/10.1038\/s41591-020-01224-2.","journal-title":"Nat Med"},{"key":"8188_CR24","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1158\/0008-5472.Can-19-0267","volume":"79","author":"J Levi","year":"2019","unstructured":"Levi J, Lam T, Goth SR, Yaghoubi S, Bates J, Ren G, et al. Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy. Cancer Res. 2019;79:3455\u201365. https:\/\/doi.org\/10.1158\/0008-5472.Can-19-0267.","journal-title":"Cancer Res"},{"key":"8188_CR25","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00259-024-06931-3","volume":"52","author":"JE Wijngaarden","year":"2025","unstructured":"Wijngaarden JE, Slebe M, Pouw JEE, Oprea-Lager DE, Schuit RC, Dickhoff C, et al. Pharmacokinetic analysis and simplified uptake measures for tumour lesion [(18)F]F-AraG PET imaging in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2025;52:719\u201329. https:\/\/doi.org\/10.1007\/s00259-024-06931-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8188_CR26","doi-asserted-by":"publisher","first-page":"eadh7968","DOI":"10.1126\/sciadv.adh7968","volume":"9","author":"N Omidvari","year":"2023","unstructured":"Omidvari N, Jones T, Price PM, Ferre AL, Lu J, Abdelhafez YG, et al. First-in-human immunoPET imaging of COVID-19 convalescent patients using dynamic total-body PET and a CD8-targeted minibody. Sci Adv. 2023;9:eadh7968. https:\/\/doi.org\/10.1126\/sciadv.adh7968.","journal-title":"Sci Adv"},{"key":"8188_CR27","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1097\/rlu.0000000000006098","volume":"50","author":"J Zhou","year":"2025","unstructured":"Zhou J, Zhou M, Chen W, Liu Y, Hai W, Huang J, et al. 68 Ga-NODAGA-SNA006 PET\/CT Imaging of Tumor CD8\u2009+\u2009T-Cell Infiltration Predicts Immunotherapy Response in Lung Cancer. Clin Nucl Med. 2025;50:1152\u201360. https:\/\/doi.org\/10.1097\/rlu.0000000000006098.","journal-title":"Clin Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08188-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08188-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08188-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:31:15Z","timestamp":1790663475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08188-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":27,"alternative-id":["8188"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08188-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.Smit, F.J. Borm, N.R. Gerards, S.E. Wiegers, Zhengxin Cai, Daniel Holden, Bert Windhorst, Yiyun Huang and Nabeel B Nabulsi report no relevant financial or nonfinancial interests related to the content of this manuscript. E.F. Smit reports institutional grants from ZonMW. He has received consulting fees paid to his institution from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Janssen, MSD, Pfizer, Roche, Sanofi, Takeda, and Merck. He has received personal honoraria for lectures and presentations from Boehringer Ingelheim and Daiichi Sankyo. He also participates on Data Safety Monitoring Boards for DSI, Taiho, Mythic, Immutep, CureVac, and mAbxience (all institutional). A.J. de Langen reports grants or contracts from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, and MSD. He participates on advisory boards for AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Pfizer, Eli Lilly, and MSD. D. Leung reports stock ownership in Bristol Myers Squibb. D.J. Grootendorst is a full-time employee of Bristol Myers Squibb and reports salary and company stock ownership as part of his employment. R. Boellaard reports research grants from Siemens Healthineers. Scott Gettinger reports research grants from Bristol Myers Squibb, BioNTech, IOVANCE, NextCure and SysImmune (all institutional). He participates in an advisory committee for BioNTech. Richard Carson reports grants from Bristol Myers Squibb, paid to the Yale University.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The imaging substudy was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Boards and ethical committees of both centers, Netherlands cancer institute and Yale school of Medicine.","order":2,"name":"Ethics","label":"<b>Ethics approval<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"<b>Consent to participate<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}]}}